Edgewise Therapeutics (EWTX) EBIT (2020 - 2026)
Edgewise Therapeutics (EWTX) posted EBIT of -$54.1 million for Q1 2026, up 3.33% sequentially from -$56.0 million in Q4 2025, and down 17.75% YoY from -$65.8 million in Q1 2025.
Edgewise Therapeutics (EWTX) EBIT (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported EBIT for 7 years, with the latest figure at -$54.1 million in Q1 2026.
- Quarterly EBIT fell 17.75% year-over-year to -$54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$199.6 million (down 17.36% YoY) and the FY2025 annual result came in at -$191.4 million, down 20.51% from the prior year.
- EBIT rose to -$54.1 million in Q1 2026 per EWTX's latest filing, from -$56.0 million in the prior quarter.
- Over five years, EBIT peaked at -$14.8 million in Q1 2022 and troughed at -$56.0 million in Q4 2025.
- A 5-year average of -$34.7 million and a median of -$34.8 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT sank 116.22% in 2022, then decreased 11.82% in 2025.
- Over 5 years, EBIT stood at -$22.1 million in 2022, then tumbled by 53.37% to -$33.9 million in 2023, then plunged by 34.49% to -$45.5 million in 2024, then slipped by 22.92% to -$56.0 million in 2025, then advanced by 3.33% to -$54.1 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$54.1 million, -$56.0 million, and -$46.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | -61.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.94 Mn |
| Mar 31, 2026 | -54.12 Mn |
| Dec 31, 2025 | -55.98 Mn |
| Sep 30, 2025 | -46.86 Mn |
| Jun 30, 2025 | -42.61 Mn |
| Mar 31, 2025 | -45.96 Mn |
| Dec 31, 2024 | -45.54 Mn |
| Sep 30, 2024 | -40.43 Mn |
| Jun 30, 2024 | -38.11 Mn |
| Mar 31, 2024 | -34.75 Mn |
| Dec 31, 2023 | -33.86 Mn |
| Sep 30, 2023 | -29.45 Mn |
| Jun 30, 2023 | -25.34 Mn |
| Mar 31, 2023 | -25.70 Mn |
| Dec 31, 2022 | -22.08 Mn |
| Sep 30, 2022 | -18.26 Mn |
| Jun 30, 2022 | -16.49 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -12.82 Mn |
| Sep 30, 2021 | -13.08 Mn |